Menu
Back to Journals » OncoTargets and Therapy » Volume 8
Comparing two assays for clinical genomic profiling: the devil is in the data [Letter of clarification]
Received 9 September 2015
Accepted for publication 9 September 2015
Published 18 September 2015 Volume 2015:8 Pages 2643—2644
Glen J Weiss, Vivek Khemka
Cancer Treatment Centers of America, Western Regional Medical Center, Goodyear, AZ, USA
It has come to our attention that the second and fourth paragraph of our Authors’ reply1 may be misconstrued as an endorsement of the Paradigm Cancer Diagnostics (PCDx) test by Cancer Treatment Centers of America, Western Regional Medical Center, Goodyear, AZ, USA. This was not our intention. We stand by the interpretation of the results of the original manuscript and the remainder of the content of the Authors’ reply. We welcome a more robust clinical comparison of these two platforms, as well as any other platform that may improve the clinical decision-making and outcomes for patients with advanced cancer.
Previous letter has been published
Dear editor
It has come to our attention that the second and fourth paragraph of our Authors’ reply1 may be misconstrued as an endorsement of the Paradigm Cancer Diagnostics (PCDx) test by Cancer Treatment Centers of America, Western Regional Medical Center, Goodyear, AZ, USA. This was not our intention. We stand by the interpretation of the results of the original manuscript and the remainder of the content of the Authors’ reply. We welcome a more robust clinical comparison of these two platforms, as well as any other platform that may improve the clinical decision-making and outcomes for patients with advanced cancer.
Disclosure
GJW is a clinical oncology advisor to Viomics and a scientific and medical advisor to Paradigm. All authors had control of the data and information submitted for the reply to the letter to the editor. The authors report no other conflicts of interest in this communication.
Reference
Squillace RM, Frampton GM, Stephens PJ, Ross JS, Miller VA. Comparing two assays for clinical genomic profiling: the devil is in the data. Onco Targets Ther. 2015;8:2237–2242. |
© 2015 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.